Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma
Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma
复制标题
DOI：
10.1097/01.tp.0000115344.18025.0b
复制
发表时间：
2004-03-15
期刊：
影响因子：
6.2
通讯作者：
Torregrosa, JV
中科院分区：
文献类型：
--
作者：
Campistol, JM;Gutierrez-Dalmau, A;Torregrosa, JV
器官移植中卡波西氏肉瘤（KS）发病率的增加与KS疱疹病毒和免疫抑制治疗的容许效应有关。钙调磷酸酶抑制剂是器官移植中免疫抑制的基石，尽管它们可能促进肿瘤进展。相比之下，西罗莫司，一种新的免疫抑制剂，显示出有效的抗肿瘤活性。我们假设，在KS患者中，从环孢素到西罗莫司的转换可以促进KS病变的消退，而不会增加移植排斥的风险。两名患有KS的肾移植受者接受了从环孢素到西罗莫司的转换。两例患者均显示KS病变完全消退，临床和功能效果良好。西罗莫司提供了一个新的和有前途的方法来管理移植后KS和其他类型的恶性肿瘤器官移植受者。
The increased incidence of Kaposi's sarcoma (KS) in organ transplantation has been related to the KS herpesvirus and the permissive effect of immunosuppressive therapy. Calcineurin inhibitors are the corner-stone of immunosuppression in organ transplantation, although they could promote tumor progression. In contrast, sirolimus, a new immunosuppressive agent, exhibits potent antitumor activity. We postulated that conversion from cyclosporine to sirolimus in patients with KS could favor regression of KS lesions without increasing the risk of graft rejection. Two renal transplant recipients with KS underwent conversion from cyclosporine to sirolimus. Both patients showed complete regression of KS lesions and excellent clinical and functional results. Sirolimus offers a new and promising approach to the management of posttransplantation KS and probably to other types of malignancies in organ transplant recipients.